GEM103

BIOLOGICAL3 trials

Sponsors

Gemini Therapeutics, Inc.

Conditions

Dry Age-related Macular DegenerationGeographic AtrophyMacular DegenerationNeovascular Age-related Macular DegenerationRetinal DegenerationRetinal Disease

Phase 1

First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration

CompletedNCT04246866

Gemini Therapeutics, Inc.Dry Age-related Macular Degeneration, Geographic Atrophy, Macular Degeneration +2

Start: 2019-12-19End: 2020-10-21Updated: 2021-02-11

Phase 2

A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration

TerminatedNCT04643886

Gemini Therapeutics, Inc.Dry Age-related Macular Degeneration, Geographic Atrophy, Macular Degeneration +2

Start: 2020-07-30End: 2022-03-21Updated: 2022-09-23

A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration

TerminatedNCT04684394

Gemini Therapeutics, Inc.Macular Degeneration, Neovascular Age-related Macular Degeneration, Retinal Degeneration +1

Start: 2020-12-29End: 2022-02-18Updated: 2022-10-31

Related Papers

A Phase I, Single Ascending Dose Study of GEM103 (Recombinant Human Complement Factor H) in Patients with Geographic Atrophy.

2022-04-1117 citations